Hemab Therapeutics Holdings, Inc. · NASDAQ:COAG
Raymond Debbane reported a 5.10% stake in Hemab Therapeutics Holdings, Inc. (Schedule 13G)
Event Aug 3, 2026 · Filed Aug 7, 2026
Raymond Debbane reported a 5.10% stake in Hemab Therapeutics Holdings, Inc., 2,366,235 shares, as a passive investor on Aug 3, 2026. Filed Aug 7, 2026 (Schedule 13G).
- Stake
- 5.10%
- Shares
- 2,366,235
- Intent
- Passive
- What changed
- Crossed above 5%
- Filed together
- 8 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Invus Public Equities, L.P. | 4.90% | 2,295,029 |
| Invus Public Equities Advisors, LLC | 4.90% | 2,295,029 |
| Invus Global Management, LLC | 4.90% | 2,295,029 |
| Siren, L.L.C. | 4.90% | 2,295,029 |
| Avicenna Life Sci Master Fund LP | 0.20% | 71,206 |
| Avicenna Life Sci Master GP LLC | 0.20% | 71,206 |
| Ulys, L.L.C. | 0.20% | 71,206 |
| Raymond Debbane | 5.10% | 2,366,235 |
Source
Related
- Hemab Therapeutics Holdings, Inc.
- Invus Public Equities, L.P.
- Hemab Therapeutics Holdings, Inc. shareholders
- Schedule 13G · Avoro Capital Advisors LLC · Aug 14, 2026
- Schedule 13G · Novo Holdings A/S · Aug 14, 2026
- Schedule 13G · Capital International Investors · Aug 12, 2026
- Schedule 13G · FMR LLC · Aug 6, 2026
- Schedule 13G · Sofinnova Crossover II SLP · Aug 5, 2026